Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study.
Fiche publication
Date publication
décembre 2014
Journal
BMC cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Pr WESTEEL Virginie
Tous les auteurs :
Borget I, Pérol M, Pérol D, Lavolé A, Greillier L, Dô P, Westeel V, Crequit J, Léna H, Monnet I, Le Caer H, Fournel P, Falchero L, Poudenx M, Vaylet F, Chabaud S, Vergnenegre A, Zalcman G, Chouaïd C,
Lien Pubmed
Résumé
The IFCT-GFPC 0502 phase III study reported prolongation of progression-free survival with gemcitabine or erlotinib maintenance vs. observation after cisplatin-gemcitabine induction chemotherapy for advanced non-small-cell lung cancer (NSCLC). This analysis was undertaken to assess the incremental cost-effectiveness ratio (ICER) of these strategies for the global population and pre-specified subgroups.
Mots clés
Adult, Aged, Antineoplastic Agents, administration & dosage, Carcinoma, Non-Small-Cell Lung, drug therapy, Cisplatin, administration & dosage, Cost-Benefit Analysis, Deoxycytidine, administration & dosage, Erlotinib Hydrochloride, Female, Health Care Costs, Humans, Induction Chemotherapy, economics, Lung Neoplasms, drug therapy, Maintenance Chemotherapy, economics, Male, Middle Aged, Prospective Studies, Quality-Adjusted Life Years, Quinazolines, administration & dosage, Survival Analysis
Référence
BMC Cancer. 2014 Dec;14:953